Evaluating online nutrition information: a scoping review of young adults’ source preferences and criteria for credibility and trustworthiness - Scorecard - MDSpire
Advertisement
Evaluating online nutrition information: a scoping review of young adults’ source preferences and criteria for credibility and trustworthiness
Clinical Scorecard: Assessing Digital Nutrition Resources: A Scoping Review of Young Adults' Preferences and Standards for Credibility and Trustworthiness
At a Glance
Category
Detail
Condition
Digital Nutrition Information Credibility
Key Mechanisms
Factors influencing trust and credibility in nutrition information include clarity, prior knowledge, and education level.
Target Population
Young adults aged 18-29 years
Care Setting
Digital health information seeking
Key Highlights
82 factors identified affecting trust and credibility in nutrition information.
Clarity of information is the most frequently reported factor.
Prior background knowledge and receiver's education also significantly influence perceptions.
Many studies neglect the author's reputation and usability of digital platforms.
Ethnicity and nationality impact assessments of information trustworthiness.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Young adults seeking nutrition information online
Emphasis on the importance of credible and trustworthy nutrition information.
Clinical Best Practices
Ensure clarity and accessibility of nutrition information.
Consider the educational background of the target audience.
Incorporate diverse perspectives in research on nutrition information.
A single case report described suicidal ideation that resolved after betahistine discontinuation and recurred after rechallenge, but the findings cannot establish causality or quantify risk.
The age-adjusted Parkinson disease death rate among US adults aged 65 years and older was 72.0 deaths per 100,000 standard population in 2024, lower than the 2021 rate, according to a National Center for Health Statistics Data Brief.
Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.